News CHMP backs Lilly's oral GLP-1 Foundayo for EU approval Eli Lilly's oral GLP-1 Foundayo has been recommended for weight reduction and type 2 diabetes in the EU, plus other CHMP decisions.
News J&J's multiple myeloma duo aces phase 3 trial Two of Johnson & Johnson's multiple myeloma bispecifics, Tecvayli and Talvey, have dramatically improved survival when used as a second-line regimen.
News Data could move J&J's Talvey earlier in myeloma therapy Johnson & Johnson's Talvey looks set to move second-line in multiple myeloma treatment, based on the results of the MonumenTAL-3 trial at EHA 2026.
News J&J says two drugs are better than one in pretreated myeloma Combining Johnson & Johnson's multiple myeloma therapies Talvey and Tecvayli shows promise in a hard-to-treat form of multiple myeloma.
News J&J bags first FDA approval for a GPRC5D drug Johnson & Johnson has become the first drugmaker to get FDA approval for a drug targeting GPRC5D, getting the nod for its bispecific antibody Talvey for a group of pat
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.